Litigation Details for Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)

Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)

Docket		Date Filed	2021-10-15
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	Plaintiff	Referred To
Patents	10,039,745; 10,154,987; 11,141,405; 9,669,008; 9,808,442
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2023-01-11	158	Opinion - Memorandum Opinion	patent), 10,039,745 (the ’745 patent), 10,772,868 (the ’868 patent), and 10,154,987 (the ’987 patent). …applications issued as U.S. Patent Nos. 9,669,008 (the ’008 patent), 11,040,023 (the ’023 patent), 11,141,405 (the…the ’405 patent), 9,808,442 (the ’442 patent), 10,786,482 (the ’482 patent), 10,918,621 (the ’621 patent…The Third Wave patents differ from the First Wave patents in that the Third Wave patents claim formulations… The precise claim limitations differ from patent to patent, but the essence of each is a stable mix-	External link to document
2023-03-08	184	Brief - Opening Brief in Support	Decl. Ex. M) ’745 patent U.S. Patent No. 10,039,745 B2 (D.I. 9-5, 7/13/21 Shrestha…’023 patent U.S. Patent No. 11,040,023 B2 (D.I. 89-1, FAC Ex. A) ’405 patent …U.S. Patent No. 11,141,405 B2 (D.I. 1, Compl. Ex. A) ’442 patent U.S. Patent No. 9,808,442… Meaning ’008 patent U.S. Patent No. 9,669,008 B1 (D.I. * 9-3, 7/13… Ex. D) ’482 patent U.S. Patent No. 10,786,482 B2 (D.I. 9-12, 7/13	External link to document